| A decade of cell death studies: Breathing new life into necroptosis I Khan, A Yousif, M Chesnokov, L Hong, II Chefetz Pharmacology & therapeutics 220, 107717, 2021 | 92 | 2021 |
| Drug toxicity assessment: cell proliferation versus cell death EV Sazonova, MS Chesnokov, B Zhivotovsky, GS Kopeina Cell Death Discovery 8 (1), 417, 2022 | 50 | 2022 |
| The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma MS Chesnokov, I Khan, Y Park, J Ezell, G Mehta, A Yousif, LJ Hong, ... Cancers 13 (6), 1369, 2021 | 25 | 2021 |
| Effect of method of deduplication on estimation of differential gene expression using RNA-seq AV Klepikova, AS Kasianov, MS Chesnokov, NL Lazarevich, AA Penin, ... PeerJ 5, e3091, 2017 | 25 | 2017 |
| FOXM1-AKT positive regulation loop provides venetoclax resistance in AML MS Chesnokov, S Borhani, M Halasi, Z Arbieva, I Khan, AL Gartel Frontiers in Oncology 11, 696532, 2021 | 22 | 2021 |
| Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells MS Chesnokov, M Halasi, S Borhani, Z Arbieva, BN Shah, R Oerlemans, ... Cell Death & Disease 12 (7), 704, 2021 | 20 | 2021 |
| Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma MS Chesnokov, PA Khesina, DA Shavochkina, IF Kustova, LM Dyakov, ... PeerJ 6, e4915, 2018 | 14 | 2018 |
| Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer MS Chesnokov, A Yadav, I Chefetz International Journal of Molecular Sciences 23 (21), 13365, 2022 | 8 | 2022 |
| Induction and detection of necroptotic cell death in mammalian cell culture M Chesnokov, I Khan, I Chefetz Detection of cell death mechanisms: Methods and protocols, 119-134, 2021 | 8 | 2021 |
| Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance I Khan, A Kaempf, S Raghuwanshi, M Chesnokov, X Zhang, Z Wang, ... Blood cancer journal 13 (1), 128, 2023 | 5 | 2023 |
| A matter of new life and cell death: programmed cell death in the mammalian ovary MS Chesnokov, AR Mamedova, B Zhivotovsky, GS Kopeina Journal of Biomedical Science 31 (1), 31, 2024 | 3 | 2024 |
| IQGAP scaffold proteins are the multifunctional regulators of cellular signaling and malignant transformation PA Skovorodnikova, MS Chesnokov, AA Budko, IF Kustova, ... Advances in molecular oncology 4 (2), 36-45, 2017 | 2 | 2017 |
| Effect of method of deduplication on estimation of differential gene expression using RNA-seq M Logacheva, A Kasianov, A Penin, M Chesnokov, A Klepikova, ... | 1 | 2017 |
| Transcriptome-based identification of PDGFA as a candidate secreted biomarker for hepatocellular carcinoma MS Chesnokov, OM Krivtsova, PA Skovorodnikova, AS Makarova, ... Вiopolymers and Cell, 2016 | 1 | 2016 |
| Abstract A057: The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma M Chesnokov, A Yousif, ilana Chefetz Molecular Cancer Therapeutics 18 (12_Supplement), A057-A057, 2019 | | 2019 |
| Abstract GMM-019: MEK INHIBITOR TRAMETINIB IN HIGH GRADE OVARIAN CANCER PROLIFERATION M Chesnokov, A Jamroze, W Ha, I Chefetz Clinical Cancer Research 25 (22_Supplement), GMM-019-GMM-019, 2019 | | 2019 |
| Abstract TMIM-064: AMPKA-LIKE PROTEINS IN OVARIAN CANCER TUMORIGENESIS AND NECROPTOSIS A Jamroze, M Chesnokov, I Chefetz Clinical Cancer Research 25 (22_Supplement), TMIM-064-TMIM-064, 2019 | | 2019 |
| MEK INHIBITOR TRAMETINIB IN HIGH GRADE OVARIAN CANCER PROLIFERATION M Chesnokov, A Jamroze, W Ha, I Chefetz CLINICAL CANCER RESEARCH 25 (22), 82-82, 2019 | | 2019 |
| AMPKA-LIKE PROTEINS IN OVARIAN CANCER TUMORIGENESIS AND NECROPTOSIS A Jamroze, M Chesnokov, I Chefetz CLINICAL CANCER RESEARCH 25 (22), 150-150, 2019 | | 2019 |
| New candidate biomarkers discerning benign liver tumors from hepatocellular carcinoma A Budko, M Chesnokov, P Skovorodnikova, D Shavochkina, I Kustova, ... Annals of Oncology 28, x12, 2017 | | 2017 |
